Endometrial immune cell ratios and implantation success in patients with recurrent implantation failure. 2023

Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
Research & Development Department, Nadezhda Women's Health Hospital, Sofia, Bulgaria; Department of Cell and developmental biology, Faculty of Biology, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria. Electronic address: rum.ganeva@gmail.com.

The objective of this study was to compare the endometrial immune cells quantities and ratios during the mid-luteal phase between women with recurrent implantation failure (RIF) with successful and unsuccessful embryo implantation. For this purpose, endometrial biopsies from 116 women aged between 29 and 46 with history of RIF undergoing Assisted Reproductive Technology (ART) without endometrial pathologies were immunohistochemically stained for CD3 + T-cells, CD4 + T-helpers, CD8 + T-killers, CD14 + monocytes, CD68 + macrophages, CD56 + NK cells and CD79α+ B-cells. Endometrial immune cells quantities and ratios were compared based on the embryo implantation outcome in the subsequent embryo transfer cycle. Spearman correlation analysis and Mann-Whitney U test were used to analyse the obtained data. Patients who experienced successful implantation at the subsequent cycle had significantly lower percentage of CD3 + T cells, and higher ratios of CD4 + /CD8 + , CD4 + /CD3 + and CD68 + /CD3 + than the patients who experienced another failure in implantation. In addition, the ratios of CD3 + /CD14 + , CD79α+ /CD14 + and CD56 + /CD14 + were significantly lower in the successful implantation group than that in the unsuccessful one. A cut off value of CD68 + /CD3 + ratio higher than 0.85 (AUC 0.67, 95% CI 0.56-0.79), CD4 + /CD3 + ratio higher than 0.19 (AUC 0.67, 95% CI 0.56-0.79) and CD4 + /CD8 + ratio higher than 0.43 (AUC 0.62, 95% CI 0.50-0.73) could be predictive factors for successful implantation in RIF patients. Knowledge on the immune cell composition could assist in the evaluation of the endometrial receptivity in RIF patients.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010064 Embryo Implantation Endometrial implantation of EMBRYO, MAMMALIAN at the BLASTOCYST stage. Blastocyst Implantation,Decidual Cell Reaction,Implantation, Blastocyst,Nidation,Ovum Implantation,Blastocyst Implantations,Decidual Cell Reactions,Embryo Implantations,Implantation, Embryo,Implantation, Ovum,Implantations, Blastocyst,Implantations, Embryo,Implantations, Ovum,Nidations,Ovum Implantations
D004624 Embryo Transfer The transfer of mammalian embryos from an in vivo or in vitro environment to a suitable host to improve pregnancy or gestational outcome in human or animal. In human fertility treatment programs, preimplantation embryos ranging from the 4-cell stage to the blastocyst stage are transferred to the uterine cavity between 3-5 days after FERTILIZATION IN VITRO. Blastocyst Transfer,Tubal Embryo Transfer,Tubal Embryo Stage Transfer,Embryo Transfers,Transfer, Embryo,Transfers, Embryo
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D027724 Reproductive Techniques, Assisted Clinical and laboratory techniques used to enhance fertility in humans and animals. Reproductive Technology, Assisted,Assisted Reproductive Technics,Assisted Reproductive Techniques,Assisted Reproductive Technic,Assisted Reproductive Technique,Assisted Reproductive Technologies,Assisted Reproductive Technology,Reproductive Technic, Assisted,Reproductive Technics, Assisted,Reproductive Technique, Assisted,Reproductive Technologies, Assisted,Technic, Assisted Reproductive,Technics, Assisted Reproductive,Technique, Assisted Reproductive,Techniques, Assisted Reproductive,Technologies, Assisted Reproductive,Technology, Assisted Reproductive

Related Publications

Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
May 2024, Annals of clinical microbiology and antimicrobials,
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
February 2023, Biomolecules,
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
March 2023, Microorganisms,
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
July 2022, Human reproduction (Oxford, England),
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
January 2019, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
September 2020, Journal of cellular and molecular medicine,
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
May 2024, Human reproduction (Oxford, England),
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
January 2021, Frontiers in immunology,
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
February 2023, American journal of reproductive immunology (New York, N.Y. : 1989),
Rumiana Ganeva, and Dimitar Parvanov, and Nina Vidolova, and Margarita Ruseva, and Maria Handzhiyska, and Katarina Arsov, and Ivon Decheva, and Dimitar Metodiev, and Veselina Moskova-Doumanova, and Georgi Stamenov
February 2022, Reproductive sciences (Thousand Oaks, Calif.),
Copied contents to your clipboard!